Live Breaking News & Updates on Qelbree

Stay informed with the latest breaking news from Qelbree on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Qelbree and stay connected to the pulse of your community

For children as young as 6 who have excessive energy and short attention span, doctors are pushing new Qelbree drug that causes suicidal thoughts and homicidal actions

Rather than gun control, America needs prescription drug CONTROL to ban these violent, psychotic-episode-inducing ADHD drugs. Introducing Qelbree (Viloxazine), the first non-stimulant [...]

United-states , America , American , Qelbree-viloxazine , Google , Supernus-pharmaceuticals , Young , Natural-news , Adhd , Bad-science , Big-pharma , Brain-function

New Adult-ADHD drug Qelbree gets FDA approval

In the flexible-dose study of adults 18 to 65 years of age, ADHD symptom score reductions...

United-states , American , Greg-mattingly , Charles-psychiatric-associates-in-st , Charles-psychiatric-associates , Qelbree , Reg-mattingly , Aryland , Nited-states , T-louis , Upernus-pharmaceuticals , Nc-

Supernus ADHD drug is FDA approved; first new 'non-stimulant' med in a decade

Supernus ADHD drug is FDA approved; first new ‘non-stimulant’ med in a decade
Supernus ADHD drug is FDA approved; first new ‘non-stimulant’ med in a decade
FDA approval of Supernus Pharmaceuticals drug Qelbree gives attention-deficit hyperactivity disorder patients another treatment option that is not classified as a Schedule II substance. It’s a different formulation of a drug that was first approved in Europe decades ago.
Shares0
Attention-deficit hyperactivity disorder (ADHD) can be addressed by several medicines already commercially available but there’s now another treatment option and it’s the first new FDA-approved drug of its type in more than a decade.

Rockville , Maryland , United-states , Jack-khattar , United-states-department-of-health , Human-services , Drug-administration , United-states-department , Supernus-pharmaceutical , Weight-loss , Obesity , Overweight

FDA approves first new ADHD drug in over a decade for children

Experts say the drug, Qelbree, may appeal to parents who don't want to give their child stimulants.

Maryland , United-states , Baltimore , American , Davidw-goodman , Johns-hopkins-school-of-medicine , Psychiatric-associates , Drug-administration , Supernus-pharmaceuticals-of-rockville , Supernus-pharmaceuticals , Suburban-psychiatric-associates

FDA OKs first new ADHD drug in over a decade for children

FDA OKs first new ADHD drug in over a decade for children
LINDA A. JOHNSON, Associated Press
April 5, 2021
FacebookTwitterEmail
This undated image provided by Supernus Pharmaceuticals in April 2021 shows bottles for different dosages of the drug Qelbree. On Friday, April 2, 2021, the U.S. Food and Drug Administration approved the medication for treating attention deficit hyperactivity disorder in children ages six through 17. (Supernus Pharmaceuticals via AP)AP
U.S. regulators have approved the first new drug in over a decade for children with ADHD, which causes inattention, hyperactivity and impulsivity.
The Food and Drug Administration late Friday OK’d Qelbree (KELL’-bree) for treating attention deficit hyperactivity disorder in children ages 6 to 17. It comes as a capsule that’s taken daily.

Maryland , United-states , Baltimore , American , Lindaa-johnson , Davidw-goodman , Johns-hopkins-school-of-medicine , Psychiatric-associates , Health-science-department , Supernus-pharmaceuticals-of-rockville , Supernus-pharmaceuticals